C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment

Breast Cancer Research

Volumn 16, Issue 3, 2014, Pages

  Wani, Nissar A ^a   Nasser, Mohd W ^a   Ahirwar, Dinesh K ^a   Zhao, Helong ^a   Miao, Zhenhua ^b   Shilo, Konstantin ^a   Ganju, Ramesh K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR RECEPTOR; GELATINASE A; GELATINASE B; STAT3 PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; CHEMOKINE RECEPTOR CXCR; CMKOR1 PROTEIN, MOUSE; COLONY STIMULATING FACTOR 1; CXCL12 PROTEIN, MOUSE; PROTEIN BINDING; SMALL INTERFERING RNA; STAT3 PROTEIN, MOUSE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ARTICLE; BREAST; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENICITY; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; LUNG METASTASIS; MACROPHAGE; MAMMARY GLAND; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; LUNG TUMOR; MACROPHAGE ACTIVATION; METABOLISM; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; RNA INTERFERENCE; SECONDARY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; FEMALE; HUMANS; LUNG NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, CXCR; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84904753552     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3665     Document Type: Article

References (75)

1. Kan N, Kuwata K, Mise K, Kodama H. Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer. Gan To Kagaku Ryoho 2010, 37:1259-1264.
2. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009, 14:645-656. doi:10.1634/theoncologist.2009-0078, 10.1634/theoncologist.2009-0078, 19608638.
3. Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, Garcia-Mata J, Garcia-Teijido P, Pelaez I, Garcia-Estevez L. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 2010, 36:33-42. doi:10.1016/j.ctrv.2009.10.001, 10.1016/j.ctrv.2009.10.001, 19883980.
4. Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 2011, 6:e23901. doi:10.1371/journal.pone.0023901PONE-D-11-12697, 10.1371/journal.pone.0023901, 3168464, 21915267.
5. Kang H, Mansel RE, Jiang WG. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int J Oncol 2005, 26:1429-1434.
6. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005, 65:967-971. 3734941, 15705897.
7. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612. doi:10.1158/0008-5472.CAN-04-1844, 10.1158/0008-5472.CAN-04-1844, 15574767.
8. Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631-21638. doi:10.1074/jbc.M300609200M300609200, 10.1074/jbc.M300609200, 12690099.
9. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213. doi:10.1084/jem.20052144, 10.1084/jem.20052144, 2118398, 16940167.
10. Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283:4283-4294. doi:10.1074/jbc.M707465200, 10.1074/jbc.M707465200, 18057003.
11. Hawkins OE, Richmond A. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2012, 14:103. doi:10.1186/bcr3092, 10.1186/bcr3092, 3496126, 22293321.
12. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, Woehl B, Leung H, Groom J, Batten M, Harvey RP, Martinez AC, Mackay CR, Mackay F. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007, 104:14759-14764. doi:10.1073/pnas.0702229104, 10.1073/pnas.0702229104, 1976222, 17804806.
13. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007, 104:15735-15740. doi:10.1073/pnas.0610444104, 10.1073/pnas.0610444104, 1994579, 17898181.
14. Ray P, Lewin SA, Mihalko LA, Lesher-Perez SC, Takayama S, Luker KE, Luker GD. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. Biochem J 2012, 442:433-442. doi:10.1042/BJ20111341, 10.1042/BJ20111341, 22142194.
15. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 2011, 286:32188-32197. doi:10.1074/jbc.M111.277038, 10.1074/jbc.M111.277038, 3173186, 21730065.
16. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. Beta-arrestin- but not G protein-mediated signaling by the " decoy" receptor CXCR7. Proc Natl Acad Sci U S A 2010, 107:628-632. doi:10.1073/pnas.0912852107, 10.1073/pnas.0912852107, 2818968, 20018651.
17. Zabel BA, Lewen S, Berahovich RD, Jaen JC, Schall TJ. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol Cancer 2011, 10:73. doi:10.1186/1476-4598-10-73, 10.1186/1476-4598-10-73, 3123309, 21672222.
18. Hernandez L, Magalhaes MA, Coniglio SJ, Condeelis JS, Segall JE. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2011, 13:R128. doi:10.1186/bcr3074, 10.1186/bcr3074, 3326570, 22152016.
19. Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ, Mentlein R. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010, 70:3299-3308. doi:10.1158/0008-5472.CAN-09-3642, 10.1158/0008-5472.CAN-09-3642, 20388803.
20. Saini MK, Vaish V, Sanyal SN. Role of cytokines and Jak3/Stat3 signaling in the 1,2-dimethylhydrazine dihydrochloride-induced rat model of colon carcinogenesis: early target in the anticancer strategy. Eur J Cancer Prev 2013, 22:215-228. doi:10.1097/CEJ.0b013e328358493200008469-201305000-00003, 10.1097/CEJ.0b013e3283584932, 23514809.
21. Wang L, Lee HK, Seo IA, Shin YK, Lee KY, Park HT. Cell type-specific STAT3 activation by gp130-related cytokines in the peripheral nerves. Neuroreport 2009, 20:663-668. doi:10.1097/WNR.0b013e32832a09f8, 10.1097/WNR.0b013e32832a09f8, 19349921.
22. Alonzi T, Middleton G, Wyatt S, Buchman V, Betz UA, Muller W, Musiani P, Poli V, Davies AM. Role of STAT3 and PI 3-kinase/Akt in mediating the survival actions of cytokines on sensory neurons. Mol Cell Neurosci 2001, 18:270-282. doi:10.1006/mcne.2001.1018S1044743101910188, 10.1006/mcne.2001.1018, 11591128.
23. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008. doi:10.1038/sj.onc.1205260, 10.1038/sj.onc.1205260, 11960372.
24. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 2009, 69:6823-6830. doi:10.1158/0008-5472.CAN-09-1684, 10.1158/0008-5472.CAN-09-1684, 2841985, 19690134.
25. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005, 335:292-299. doi:10.1016/j.bbrc.2005.07.075, 10.1016/j.bbrc.2005.07.075, 16081048.
26. Clarkson RW, Boland MP, Kritikou EA, Lee JM, Freeman TC, Tiffen PG, Watson CJ. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 2006, 20:675-685. doi:10.1210/me.2005-0392, 10.1210/me.2005-0392, 16293640.
27. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66:1-9. doi:10.1016/j.critrevonc.2007.07.004, 10.1016/j.critrevonc.2007.07.004, 17913510.
28. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78. doi:10.1038/nrc1256nrc1256, 10.1038/nrc1256, 14708027.
29. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740. 10.1084/jem.193.6.727, 2193412, 11257139.
30. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007, 67:5064-5066. doi:10.1158/0008-5472.CAN-07-0912, 10.1158/0008-5472.CAN-07-0912, 17545580.
31. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006, 95:272-281. doi:10.1038/sj.bjc.6603240, 10.1038/sj.bjc.6603240, 2360657, 16832418.
32. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008, 267:204-215. doi:10.1016/j.canlet.2008.03.028, 10.1016/j.canlet.2008.03.028, 18448242.
33. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005, 3:1-13.
34. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999, 17:163-170. 10.1023/A:1006689719505, 10411109.
35. Balasubramanian A, Ganju RK, Groopman JE. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem 2003, 278:35755-35766. doi:10.1074/jbc.M302889200M302889200, 10.1074/jbc.M302889200, 12824191.
36. Fernandis AZ, Cherla RP, Ganju RK. Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45. J Biol Chem 2003, 278:9536-9543. doi:10.1074/jbc.M211803200M211803200, 10.1074/jbc.M211803200, 12519755.
37. Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 2003, 188:1192-1204. doi:10.1086/378643, 10.1086/378643, 14551890.
38. Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009, 8:3117-3129. doi:10.1158/1535-7163.MCT-09-0448, 10.1158/1535-7163.MCT-09-0448, 19887554.
39. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004, 23:157-167. doi:10.1038/sj.onc.12069101206910, 10.1038/sj.onc.1206910, 14712221.
40. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, Ganju RK. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012, 72:604-615. doi:10.1158/0008-5472.CAN-11-0669, 10.1158/0008-5472.CAN-11-0669, 3271140, 22158945.
41. Sneh A, Deol YS, Ganju A, Shilo K, Rosol TJ, Nasser MW, Ganju RK. Differential role of psoriasin (S100A7) in estrogen receptor alpha positive and negative breast cancer cells occur through actin remodeling. Breast Cancer Res Treat 2013, 136:727-739. doi:10.1007/s10549-013-2491-4.
42. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. doi:10.1038/nature03799, 10.1038/nature03799, 1283098, 16049480.
43. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 2013, 139:71-80. doi:10.1007/s10549-013-2485-2, 10.1007/s10549-013-2485-2, 23609470.
44. Tarkkonen K, Ruohola J, Harkonen P. Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells. Growth Factors 2010, 28:256-267. doi:10.3109/08977191003745480, 10.3109/08977191003745480, 20370578.
45. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009, 114:263-275. doi:10.1007/s10549-008-0011-8, 10.1007/s10549-008-0011-8, 2764248, 18409071.
46. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22:4150-4165. doi:10.1038/sj.onc.12064791206479, 10.1038/sj.onc.1206479, 12833138.
47. Zhang SS, Liu MG, Kano A, Zhang C, Fu XY, Barnstable CJ. STAT3 activation in response to growth factors or cytokines participates in retina precursor proliferation. Exp Eye Res 2005, 81:103-115. doi:10.1016/j.exer.2005.01.016, 10.1016/j.exer.2005.01.016, 15978261.
48. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292. 10.1084/jem.176.1.287, 2119288, 1613462.
49. Utsunomiya Y, Omura K, Yokoo T, Imasawa T, Kawamura T, Abe A, Hirano K, Mitarai T, Maruyama N, Sakai O. Macrophage-colony stimulating factor (M-CSF) enhances proteinuria and recruitment of macrophages into the glomerulus in experimental murine nephritis. Clin Exp Immunol 1996, 106:286-296. 10.1046/j.1365-2249.1996.d01-831.x, 2200600, 8918575.
50. Le Meur Y, Tesch GH, Hill PA, Mu W, Foti R, Nikolic-Paterson DJ, Atkins RC. Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. J Leukoc Biol 2002, 72:530-537.
51. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 2004, 101:10602-10607. doi:10.1073/pnas.04041001010404100101, 10.1073/pnas.0404100101, 489981, 15249664.
52. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049. doi:10.1126/science.1067431296/5570/1046, 10.1126/science.1067431, 2788989, 12004111.
53. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011, 20:538-549. doi:10.1016/j.ccr.2011.08.025, 10.1016/j.ccr.2011.08.025, 3293160, 22014578.
54. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. doi:10.1038/nature11412, 10.1038/nature11412, 3465532, 23000897, The Cancer Genome Atlas Network.
55. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404. doi:10.1158/2159-8290.CD-12-0095, 10.1158/2159-8290.CD-12-0095, 3956037, 22588877.
56. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550. doi:10.1038/nrc1388nrc1388, 10.1038/nrc1388, 15229479.
57. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005, 14:360-367. doi:10.1016/j.breast.2004.12.007, 10.1016/j.breast.2004.12.007, 16216737.
58. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931. doi:10.1158/1078-0432.CCR-09-2329, 10.1158/1078-0432.CCR-09-2329, 20484021.
59. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N, Imamura M. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000, 6:3530-3535.
60. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005, 12:84-89. doi:10.1038/sj.cgt.7700770, 10.1038/sj.cgt.7700770, 15472715.
61. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004, 18:1240-1242. doi:10.1096/fj.03-0935fje03-0935fje.
62. Luker KE, Gupta M, Steele JM, Foerster BR, Luker GD. Imaging ligand-dependent activation of CXCR7. Neoplasia 2009, 11:1022-1035. 2745668, 19794961.
63. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 2010, 29:4599-4610. doi:10.1038/onc.2010.212, 10.1038/onc.2010.212, 3164491, 20531309.
64. Xue TC, Chen RX, Ye SL, Sun RX, Chen J, Tang ZY. Different expressions of chemokine receptors in human hepatocellular carcinoma cell lines with different metastatic potentials. Zhonghua Gan Zang Bing Za Zhi 2007, 15:261-265.
65. Xue TC, Chen RX, Ren ZG, Zou JH, Tang ZY, Ye SL. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. Oncol Rep 2013, 30:105-110. doi:10.3892/or.2013.2442.
66. Takanami I, Ohnishi H. Study of surgical resection of sternal metastasis from carcinoma of the breast. Gan No Rinsho 1989, 35:1735-1738.
67. Zhang YW, Zhang ZX, Miao ZH, Ding J. The telomeric protein TRF2 is critical for the protection of A549 cells from both telomere erosion and DNA double-strand breaks driven by salvicine. Mol Pharmacol 2008, 73:824-832. doi:10.1124/mol.107.039081.
68. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004, 165:1449-1460. doi:10.1016/S0002-9440(10)63403-7, 10.1016/S0002-9440(10)63403-7, 1618660, 15509516.
69. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011, 19:429-431. doi:10.1016/j.ccr.2011.03.018, 10.1016/j.ccr.2011.03.018, 3111086, 21481782.
70. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004, 3:555-564. doi:10.1038/nrd1441nrd1441, 10.1038/nrd1441, 15232577.
71. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013, 15:848-862. 3689247, 23814496.
72. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995, 1:1257-1260. 10.1038/nm1295-1257, 7489405.
73. Kruse J, von Bernstorff W, Evert K, Albers N, Hadlich S, Hagemann S, Gunther C, van Rooijen N, Heidecke CD, Partecke LI. Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis 2013, 28:1337-1349. doi:10.1007/s00384-013-1703-z, 10.1007/s00384-013-1703-z, 23657400.
74. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997, 80:1529-1537. doi:10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F, 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F, 9362419.
75. van der Bij GJ, Bogels M, Oosterling SJ, Kroon J, Schuckmann DT, de Vries HE, Meijer S, Beelen RH, van Egmond M. Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett 2008, 262:77-86. doi:10.1016/j.canlet.2007.11.040, 10.1016/j.canlet.2007.11.040, 18187256.